Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.
about
BH3 mimetics to improve cancer therapy; mechanisms and examplesLyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.Regulators of apoptosis: suitable targets for immune therapy of cancer.Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells.Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.Cancer treatment: the combination of vaccination with other therapies.Liposomes containing (-)-gossypol-enriched cottonseed oil suppress Bcl-2 and Bcl-xL expression in breast cancer cells.The role of apoptosis in radiation oncology.The functioning antigens: beyond just as the immunological targets.Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells.Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.Therapeutic cancer vaccines in combination with conventional therapy.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.RNA aptamers targeting the cell death inhibitor CED-9 induce cell killing in Caenorhabditis elegans.BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice.Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells.Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot.Antisense radiotherapy: targeting full-size mdrl mRNA with 125I-labelled oligonucleotides.
P2860
Q24655483-0B0A13CC-337E-45CC-A454-E126DA56E090Q34309928-EF3E0481-D770-48A3-A3FA-DD099B0CBBF7Q36088627-4E196AA1-0E39-4051-9CEE-B7F797EAE67FQ36111911-621C0EF0-6CA0-46AA-9788-F5563F9AF3E3Q36158713-F7A29EE7-F557-4C69-BA21-D2BAA7A80FFAQ36337587-E6D37F16-2CCB-4983-867E-E45A4EF58276Q36504936-ECBD0F6D-BE2F-4D80-8456-DE94A4691255Q36625664-8C4A6152-FE3A-400E-8E17-64BFE1DB517EQ36725286-572FBDB4-A6DA-4260-8D91-68842897EBDFQ37089001-C74CF186-140A-4338-9CC0-3A3C13044469Q37257494-B9DDD981-502E-4E63-A395-359CA8E43F58Q37413111-0D23AB4D-9EEF-4B33-A240-F48B43D09B13Q37483795-56C4B104-E569-45B8-9FCA-B0DFEBB8BA34Q37706871-506B518B-3DD9-4E8D-97BC-43CA5CF4E267Q37713757-58EF1C7C-5A10-4C2D-BE94-5F5B50AAA1C6Q37771267-291FAC5C-BB62-44BD-BC70-03D5E098C5F1Q37838167-68C0A41A-C1BC-4DDD-B27D-4F376B90C49AQ38316055-7E583A83-29B3-4E5B-9DAA-C36B7C81DE81Q38779981-C3080616-9BC3-4B64-BA10-CF34017764BDQ38993215-35FB060F-F519-4CCE-81B4-473B38D4E978Q39314317-DCBA9AE0-9472-48EB-A397-5DF4D7779A5BQ40576657-F1F07E50-C1CB-4547-9D48-55ED2374C47AQ41889515-F17EE264-E3E1-4500-A249-DF7311BC87CEQ46375071-5C04D197-07FE-474D-B224-13B8AB5B6DF9
P2860
Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Recent advances in the develop ...... s in the Bcl-2 protein family.
@ast
Recent advances in the develop ...... s in the Bcl-2 protein family.
@en
type
label
Recent advances in the develop ...... s in the Bcl-2 protein family.
@ast
Recent advances in the develop ...... s in the Bcl-2 protein family.
@en
prefLabel
Recent advances in the develop ...... s in the Bcl-2 protein family.
@ast
Recent advances in the develop ...... s in the Bcl-2 protein family.
@en
P2860
P356
P1433
P1476
Recent advances in the develop ...... s in the Bcl-2 protein family.
@en
P2093
Johnson DE
Shangary S
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403029
P577
2003-08-01T00:00:00Z
P5875
P6179
1015469961